作為NIK抑制劑的新穎的經取代氰基吲哚啉衍生物农业专利-农业学术服务平台

发明人:: IAN, STANSFIELD,伊恩　斯坦斯菲尔德,伊恩　斯坦斯菲爾德,OLIVIER ALEXIS GEORGES, QUEROLLE,奥利弗亚历西斯乔治　凯罗勒,奧利弗亞歷西斯喬治　凱羅勒,VIRGINIE SOPHIE, PONCELET,维吉尼亚苏菲　彭赛列,維吉尼亞蘇菲　彭賽列,GERHARD MAX, GROSS,格哈德麦克斯　葛洛斯,格哈德麥克斯　葛洛斯,EDGAR, JACOBY,伊恩斯坦斯菲尔德,伊恩斯坦斯菲爾德,奥利弗亚历西斯乔治凯罗勒,奧利弗亞歷西斯喬治凱羅勒,维吉尼亚苏菲彭赛列,維吉尼亞蘇菲彭賽列,格哈德麦克斯葛洛斯,格哈德麥克斯葛洛斯

摘要：: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.本發明涉及可用於在哺乳動物中進行治療和/或預防的藥物試劑，並且具體來說涉及NF-κB誘導激酶（NIK - 也稱為MAP3K14）之抑制劑，該等抑制劑可用於治療如下疾病，比如癌症、炎性障礙、代謝失調以及自體免疫疾病。本發明還針對包含此類化合物之醫藥組成物；並且針對此類化合物或醫藥組成物用於預防或治療疾病之用途，該等疾病比如癌症、炎性障礙、包括肥胖症和糖尿病之代謝失調、以及自體免疫疾病。